Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

Description: About Acquired Orphan Blood Diseases Therapeutics
Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. The acquired orphan blood diseases are developed in the blood after the post fetal life; they are not caused because of genetic reasons. The major orphan blood diseases that contribute to acquired orphan blood diseases are the following: ITP, MDS, MF PNH, and PV.

The analysts forecast the Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS.

The report, the Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Acquired Orphan Blood Diseases Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
- Americas
- APAC
- EMEA

Key Vendors
- Alexion Pharmaceuticals
- Amgen
- Celgene
- F. Hoffmann- La Roche
- GlaxoSmithKline
- Incyte

Other Prominent Vendors
- Cyclacel Pharmaceuticals
- CTI Biopharma (Cell Therapeutics)
- Eli Lilly
- Gilead Sciences
- Onconova Therapeutics
- MebVax Therapeutics
- Novartis
- Sanofi
- Shire Pharmaceuticals
- S* Bio Pte

Market Drivers
- Exemption from Pricing Obstacle
- For a full, detailed list, view our report

Market Challenges
- Companies Hesitant to Invest in Rare Diseases Therapeutics
- For a full, detailed list, view our report

Market Trends
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key Market Trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Contents:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1 Soliris
04.2 Nplate
04.3 Revlimid
04.4 Vidaza
04.5 Promacta
04.6 Jakafi
04.7 Rituxan
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Diseases Overview
07.1 ITP
07.1.1 Understanding the Disease
07.1.2 Epidemiology
07.1.3 Etiology
07.1.4 Pathophysiology
07.1.5 Management of Disease
07.2 MDS
07.2.1 Understanding the Disease
07.2.2 Epidemiology
07.2.3 Etiology
07.2.4 Pathophysiology
07.2.5 Management of Disease
07.3 MF
07.3.1 Understanding the Disease
07.3.2 Epidemiology
07.3.3 Etiology
07.3.4 Pathophysiology
07.3.5 Management of Disease
07.4 PNH
07.4.1 Understanding the Disease
07.4.2 Epidemiology
07.4.3 Etiology
07.4.4 Pathophysiology
07.4.5 Management of Disease
07.5 PV
07.5.1 Understanding the Disease
07.5.2 Epidemiology
07.5.3 Etiology
07.5.4 Pathophysiology
07.5.5 Management of Disease
07.6 Pipeline Analysis
07.7 Emerging Treatment Options
19.4.7 Business Strategy
19.4.8 Recent Developments
19.4.9 SWOT Analysis
19.5 Incyte
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Revenue Segmentation by 2013
19.5.4 Revenue Segmentation by 2012 and 2013
19.5.5 Geographical Segmentation
19.5.6 Business Strategy
19.5.7 Recent Developments
19.5.8 SWOT Analysis
19.6 GlaxoSmithKline
19.6.1 Key Facts
19.6.2 Business Overview
19.6.3 Business Segmentation
19.6.4 Business Segmentation by Revenue 2012 and 2013
19.6.5 Sales by Geography
19.6.6 Pipeline Products
19.6.7 Business Strategy
19.6.8 Key Information
19.6.9 SWOT Analysis
19.6.10 Strengths
19.6.11 Weaknesses
19.6.12 Opportunities
19.6.13 Threats
20. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of ITP
Exhibit 3: Snapshot of MDS
Exhibit 4: Snapshot of MF
Exhibit 5: Snapshot of PNH
Exhibit 6: Snapshot of PV
Exhibit 8: Global Acquired Orphan Blood Diseases Therapeutics Market Segmentation by Indication Type
Exhibit 9: Global Acquired Orphan Blood Diseases Therapeutics Market Revenue Comparison by Indication, 2014 and 2019 (US$ million)
Exhibit 10: Global Acquired Orphan Blood Diseases Therapeutics Market Percent Share by Indication, 2014 and 2019
Exhibit 16: Geographical Segmentation of Global Acquired Orphan Blood Diseases Therapeutics Market in 2014
Exhibit 17: Marketing Exclusivity for Orphan Drugs in Some Regions
Exhibit 18: Revenue Comparison of Top Drugs for Acquired Orphan Blood Diseases Therapeutics market in 2013 (US$ million)
Exhibit 19: Revenue Comparison and YoY Growth for Soliris from 2012-2014 (US$ million)
Exhibit 20: Global Market Forecast for Soliris from 2014-2019 (US$ million)
Exhibit 21: Revenue Comparison and YoY Growth for Nplate from 2011-2013 (US$ million)
Exhibit 22: Revenue Comparison and YoY Growth for Revlimid from 2011-2013 (US$ million)
Exhibit 23: Revenue Comparison and YoY Growth for Vidaza from 2011-2013 (US$ million)
Exhibit 24: Revenue Comparison for Rituxan from 2012-2013 (US$ million)
Exhibit 25: Revenue Comparison and YoY Growth for Promacta 2011-2014 (US$ million)
Exhibit 26: Revenue Comparison for Jakafi from 2012-2013 (US$ million)
Exhibit 27: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 28: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 29: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 30: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 31: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 32: Celgene: Sales by Geography 2013
Exhibit 33: Alexion: Geographical Segmentation by Revenue 2013
Exhibit 34: Amgen: Business Segmentation by Revenue 2013
Exhibit 35: Amgen: Product Portfolio by Revenue 2013
Exhibit 36: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 37: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 38: Incyte Corporation: Revenue Segmentation by 2013 (US$ million)
Exhibit 39: Incyte Corporation: Revenue Segmentation by 2012 and 2013 (US$ million)
Exhibit 40: Incyte Corporation: Geographical Segmentation
Exhibit 41: GlaxoSmithKline: Business Segmentation 2013
Exhibit 42: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 43: GlaxoSmithKline: Sales by Geography 2013
Exhibit 44: GlaxoSmithKline: Pipeline Products 2013

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3129432/](http://www.researchandmarkets.com/reports/3129432/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/.

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
Web Address: http://www.researchandmarkets.com/reports/3129432/
Office Code: SCH3QV2Y

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World